Evidence map›Paper›PMID 16410617›Full record

ArticleNucleic acids research2006

Characterization of sequences and mechanisms through which ISE/ISS-3 regulates FGFR2 splicing.

Ruben H Hovhannisyan, Claude C Warzecha, Russ P Carstens

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Characterization of Alternative Splicing in High-Risk Wilms' Tumors.International journal of molecular sciences · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Fas-activated serine/threonine phosphoprotein (FAST) is a regulator of alternative splicing.Proceedings of the National Academy of Sciences of the United States of America · 2007
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ruben H HovhannisyanDepartment of Medicine, University of Pennsylvania School of Medicine, 700 Clinical Research Building, 415 Curie Blvd., Philadelphia, PA 19104, USA.
Claude C Warzecha
Russ P Carstens
University of Pennsylvania · US

Funding

REGULATION OF FGF RECEPTOR SPLICING IN PROSTATE CANCERR01CA093769 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARSTENS, RUSS PAUL · 2003 to 2007
$1.3M
NCI NIH HHS CA093769NCI NIH HHS R01 CA093769
6 · The paper itself

Abstract

Alternative splicing of fibroblast growth factor receptor-2 (FGFR2) mutually exclusive exons IIIb and IIIc results in highly cell-type-specific expression of functionally distinct receptors, FGFR2-IIIb and FGFR2-IIIc. We previously identified an RNA cis-element, ISE/ISS-3, that enhanced exon IIIb splicing and silenced exon IIIc splicing. Here, we have performed comprehensive mutational analysis to define critical sequence motifs within this element that independently either enhance splicing of upstream exons or repress splicing of downstream exons. Such analysis included use of a novel fluorescence-based splicing reporter assay that allowed quantitative determination of relative functional activity of ISE/ISS-3 mutants using flow cytometric analysis of live cells. We determined that specific sequences within this element that mediate splicing enhancement also mediate splicing repression, depending on their position relative to a regulated exon. Thus, factors that bind the element are likely to be coordinately involved in mediating both aspects of splicing regulation. Exon IIIc silencing is dependent upon a suboptimal branchpoint sequence containing a guanine branchpoint nucleotide. Previous studies of exon IIIc splicing in HeLa nuclear extracts demonstrated that this guanine branchsite primarily impaired the second step of splicing suggesting that ISE/ISS-3 may block exon IIIc inclusion at this step. However, results presented here that include use of newly developed in vitro splicing assays of FGFR2 using extracts from a cell line expressing FGFR2-IIIb strongly suggest that cell-type-specific silencing of exon IIIc occurs at or prior to the first step of splicing.

Indexed as

Alternative SplicingRegulatory Sequences, Ribonucleic AcidBase SequenceCell LineCell NucleusConsensus SequenceDNA Mutational AnalysisExonsFlow CytometryGuanineHeLa CellsHumansIntronsMolecular Sequence DataReceptor, Fibroblast Growth Factor, Type 2RNA Splice SitesGuanineReceptor, Fibroblast Growth Factor, Type 2Regulatory Sequences, Ribonucleic AcidRNA Splice Sites

Identifiers

PMID16410617
PMCPMC1331989
OpenAlexW2167775804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.